LEXINGTON — A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.
A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.
The study, led by UK Markey Cancer Center radiation oncologist Charles Kunos, M.D., and published in Frontiers in Oncology, validates that the radioactive drug 212Pb-DOTAM-GRPR1 may be useful in the treatment of persistent, recurrent, or metastatic cervical cancer.
New Radiopharmaceutical Could Treat Cancer: Research miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
A new study is showing improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumor cells.